Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor α (TNF-α) production: Selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3- carbonitriles

Journal of Medicinal Chemistry

Volumn 50, Issue 19, 2007, Pages 4728-4745

  Green, Neal ^a   Hu, Yonghan ^a   Janz, Kristin ^a   Li, Huan Qiu ^a   Kaila, Neelu ^a   Guler, Satenig ^a   Thomason, Jennifer ^a   Joseph McCarthy, Diane ^a   Tam, Steve Y ^a   Hotchandani, Rajeev ^a   Wu, Junjun ^a   Huang, Adrian ^a   Wang, Qin ^a   Leung, Louis ^a   Pelker, Jefferey ^a   Marusic, Suzana ^a   Hsu, Sang ^a   Telliez, Jean Baptiste ^a   Hall, J Perry ^a   Cuozzo, John W ^a,b   Lin, Lih Ling ^a   more..

^a PFIZER INC   (United States)

^b Praecis Pharmaceuticals Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 ANILINO 6 AMINOQUINOLINE 3 CARBONITRILE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 8 BROMO 4 (3 CHLORO 4 FLUOROPHENYLAMINO) 6 [(1 METHYL 1H IMIDAZOL 4 YL)METHYLAMINO]QUINOLINE 3 CARBONITRILE; AMG 548; AMINOQUINOLINE DERIVATIVE; BMS 561392; DORAMAPIMOD; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; NAPHTHYRIDINE 3 CARBONITRILE; PROTEIN SERINE THREONINE KINASE; QUINOLINE 3 CARBONITRILE; TMI 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR PROGRESSION LOCI 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; FIRST PASS EFFECT; IC 50; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOLECULAR MODEL; NONHUMAN; PLASMA CLEARANCE; RAT; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

AMINOQUINOLINES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CRYSTALLOGRAPHY, X-RAY; FEMALE; HUMANS; IMIDAZOLES; MAP KINASE KINASE KINASES; MICROSOMES, LIVER; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34648836424     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070436q     Document Type: Article

References (49)

1. Choy, E. H. S.; Panayi, G. S. P. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 2001, 344, 907-916.
2. Feldmann, M.; Brennan, F. M.; Foxwell, B. M.; Maini, R. N. The role of TNF-α and IL-1 in rheumatoid arthritis. Curr. Dir. Autoimmun. 2001, 3, 188-199.
3. Feldmann, M.; Maini, R. N. Anti-TNF-alpha therapy of rheumatoid arthritis: What have we learned? Ann. Rev. Immuol. 2001, 19, 163-178.
4. Zhang, Y.; Xu, J.; Levin, J.; Hegen, M.; Li, G.; Robertshaw, H.; Brennan, F.; Cummons, T.; Clarke, D.; Vansell, N.; Nickerson-Nutter, C.; Barone, D.; Mohler, K.; Black, R.; Skotnicki, J.; Gibbons, J.; Feldmann, M.; Frost, P.; Larsen, G.; Lin, L.-L. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S) -thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-α-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J. Pharmacol. Exp. Ther. 2004, 309, 348-355.
5. Jarvis, B.; Faulds, D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999, 57, 945-966.
6. Maini, R.; St. Clair, E. W.; Breedveld, F.; Furst, D.; Kalden, M.; Weisman, J.; Smolen, M.; Emery, P.; Harriman, G.; Feldmann, M.; Lipsky, P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354, 1932-1939.
7. Kumar, S.; Boehm, J.; Lee, J. C. p38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discovery 2003, 2, 717-726.
8. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9, 268-272.
9. Salituro, F. G.; Bemis, G. W.; Germann, U. A.; Duffy, J. P.; Galullo, V. P.; Gao, H.; Harrington, E. M.; Wilson, K. P.; Su, M. S. Discovery of VX-745: A Novel, Orally Bioavailable and Selective p38 MAP Kinase Inhibitor. Presented at the 27th National Medicinal Chemistry Symposium, Kansas City, MO, 2000.
10. Lee, R. L.; Dominguez, C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38α protein. Curr. Med. Chem. 2005, 12, 2979-2994.
11. Sasai, H.; Higashi, T.; Nakamori, S.; Miyoshi, J.; Suzuki, F.; Nomura, T.; Kakunaga, T. Syrian hamster embryo cell lines useful for detecting transforming genes in mouse tumours: detection of transforming genes in X-ray-related mouse tumours. Br. J. Cancer 1993, 67, 262-267.
12. Dumitru, C. D.; Ceci, J. D.; Tsatsanis, C.; Konoyiannis, D.; Stamatakis, K.; Lin, J. H.; Patriotis, C.; Jenkins, N. A.; Copeland, N. G.; Kollias, G.; Tsichlis, P. N. TNF-α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway Nat. Med. 2003, 9, 61-67.
13. Eliopoulos, A. G.; Dumitru, C. D.; Wang, C. C.; Cho, J.; Tsichlis, P. N. Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. EMBO J. 2002, 21, 4831-4840.
14. Dumitru, C. D.; Ceci, J. D.; Tsatsanis, C.; Konoyiannis, D.; Stamatakis, K.; Lin, J. H.; Patriotis, C.; Jenkins, N. A.; Copeland, N. G.; Kollias, G.; Tsichlis, P. N. TNF-α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway Cell 2000, 103, 1071-1083.
15. Lin, X.; E. T.; Cunningham, E. T., Jr.; Mu, Y.; Gelziunas, R.; Greene, W. C. The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-κB acting through the NF-κB-inducing kinase and IκB kinases. Immunity 1999, 10, 271-280.
16. Chiarello, M.; Marinissen, M. J.; Gutkind, J. S. Multiple mitogen-activated protein kinase signaling pathways connect the Cot oncoprotein to the c-jun promoter and to cellular transformation Mol. Cell. Biol. 2000, 20, 1747-1758.
17. Salmeron, A.; Ahmad, T. B.; Carlile, G. W.; Pappin, D.; Narsimhan, R. P.; Ley, S. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO J. 1996, 15, 817-826.
18. Luciano, B. S.; Hsu, S.; Channavajhala, P. L.; Lin, L-L.; Cuozzo, J. W. Phosphorylation of threonine 290 in the activation loop of Tpl2/Cot is necessary but not sufficient for kinase activity. J. Biol. Chem. 2004, 279, 52117-52123.
19. Gavrin, L. K.; Green, N.; Hu, Y.; Janz, K.; Kaila, N.; Li, H.-Q.; Tam, S. Y.; Thomason, J. R.; Gopalsamy, A.; Ciszewski, G.; Cuozzo, J. W.; Hall, J. P.; Hsu, S.; Telliez, J.-B.; Lin, L.-L. Inhibition of Tpl2 kinase and TNF-α production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships. Bioorg. Med. Chem. Lett. 2005, 15, 5288-5292.
20. Hu, Y.; Green, N.; Gavrin, L. K.; Janz, K.; Kaila, N.; Li, H.-Q.; Thomason, J. R.; Cuozzo, J. W.; Hall, J. P.; Hsu, S.; Nickerson-Nutter, C.; Telliez, J.-B.; Lin, L.-L.; Tam, S. Y. Inhibition of Tpl2 kinase and TNF-α production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis. Bioorg. Med. Chem. Lett. 2006, 16, 6067-6072.
21. Part of this work has been presented: Green, N.; Guler, S.; Hotchandani, R.; Hu, Y.; Janz, K.; Kaila, N.; Li, H-Q.; Thomason, J.; Tam, S.; Wu, J.; Joseph-McCarthy, D.; Cuozzo, J.; Hall, J. P.; Lin, L-L. Selective Inhibition of Tpl2 Kinase and TNF Production with Quinoline-3-carbonitriles for the Treatment of Rheumatoid Arthritis. Presented at the 14th International Conference of the Inflammation Research Association, Cambridge, MD, October 15-19, 2006; SA33.
22. Wissner, A.; Overbeek, E.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Mamuya, N.; Rosfjord, E. C.; Discafani, C.; Davis, R.; Shi, X.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W. A.; Nilakantan, R.; Shen, R.; Wang, Y.-F.; Greenberger, L. M.; Tsou, H.-R. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem. 2003, 46, 49-63 and references cited therein.
23. Testaferri, L.; Tingoli, M.; Tiecco, M. A convenient synthesis of aromatic thiols from unactivated aryl halides. Tetrahedron Lett. 1980, 21, 3099-3100.
24. + ATPase. Eur. J. Med. Chem. 1991, 26, 143-158.
25. Mohamadi, F.; Spees, M. M.; Staten, G. S.; Marder, P.; Kipka, J. K.; Johnson, D. A.; Boger, D. L.; Zarrinmayeh, H. Total synthesis and biological properties of novel antineoplastic (chloromethyl)-furanoindolines: an asymmetric hydroboration mediated synthesis of the alkylation subunits. J. Med. Chem. 1994, 37, 232-239.
26. Grunewald, G. L.; Vidyadhar, M.; Pazhenchevsky, M.; Pleiss, M. A.; Sall, D. J.; Seibel, W. L.; Reitzle, T. J. Synthesis of conformationally defined analogues of norfenfluramine. A highly stereospecific synthesis of amines from alcohols in the benzobicyclo[2.2.1]heptene system. J. Org. Chem. 1983, 48, 2321-2327.
27. Kim, D.-I.; Kim, H.-Y.; Kwon, L.-S.; Park, S.-D.; Jeon, G.-H.; Jung, K.-Y.; Min, J.-K.; Nam, W-H.; Lee, K.; Chung, Y.-S.; Tanabe, S.; Kozono, T. Synthesis and biological activity of KCB-328 and its analogues: novel class III antiarrhythmic agents with little reverse frequency dependence. Bioorg. Med. Chem. Lett. 1999, 9, 85-90.
28. Standard reductive amination conditions were employed in most cases. See Experimental Section and ref 19 for specific examples.
29. Kiddle, J. J. Microwave irradiation in organophosphorus chemistry. Part 2: synthesis of phosphonium salts. Tetrahedron Lett. 2000, 41, 1339-1341.
30. Trecourt, F.; Breton, G.; Bonnet, V.; Mongin, F.; Marsais, F.; Queguiner, G. New syntheses of substituted pyridines via bromine-magnesium exchange. Tetrahedron 2000, 56, 1349-1360.
31. Paul, R.; Brockman, J. A.; Hallet, W. A.; Hanifin, J. W.; Tarrant, M. E.; Torley, L. W.; Callahan, F. M.; Fabio, P. F.; Johnson, B. D.; Lenhard, R. H.; Schaub, R. E.; Wissner, A. Imidazo[1,5-d][1,2,4]triazines as potential antiasthma agents. J. Med. Chem. 1985, 28, 1704-1716.
32. Groziak, M. P.; Wei, L. Regioselective formation of imidazol-2-yllithium, imidazol-4-yllithium, and imidazol-8-yllithium species. J. Org. Chem. 1991, 56, 4296-4300.
33. For examples of this widely used approach, see refs 10 and 11 cited in ref 19.
34. Stamos, J.; Sliwkoski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277, 46265-46272.
35. An example of this strategy: Hennequin, L. F.; Allen, J.; Breed, J.; Curwen, J.; Fennell, M.; Green, T. P.; Lambert-van der Brempt, C.; Morgentin, R.; Norman, R. A.; Olivier, A.; Otterbein, L.; Ple, P. A.; Warin, N.; Costello, G. N-(5-Chloro-1,3-benzodioxol-4-yl)-2-[2-(4-methylpiperazin-1-yl)ethoxy] -5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem. 2006, 49, 6465-6488.
36. Lake, B. Preparation and characterization of microsomal fractions for studies on xenobiotic metabolism. In Biochemical Toxicology: A Practical Approach; Snell, K., Mullock, B., Eds.; IRL Press: Oxford, U.K., 1987; pp 183-215.
37. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
38. Omura, T.; Sato, R. The carbon-monoxide binding pigment of liver microsomes. J. Biol. Chem. 1964, 239, 2370-2378.
39. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
40. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 2004, 47, 1750-1759.
41. Miranker, A.; Karplus, M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins 1991, 11, 29-34.
42. Evensen, E.; Joseph-McCarthy, D.; Karplus, M. MCSSv2, version 2.1; Harvard University: Cambridge, MA.
43. (a) Kerns, E. H.; Di, L. Pharmaceutical profiling in drug discovery. Drug Discovery Today 2003, 8, 316-323.
44. (b) Avdeef, A.; Voloboy, D.; Foreman, A. Dissolution-Solubility of Multiprotic Drugs: pH, Buffer, Salt, Dual-Solid, and Aggregation Effects. In ADME-TOX Approaches; Testa, B., van de Waterbeemd, H., Eds.; Comprehensive Medicinal Chemistry II, Vol. 5; Elsevier: Oxford, U.K., 2006; pp 399-423.
45. (c) Avdeef, A.; Testa, B. Physicochemical profiling in drug research: a brief state-of-the-art of experimental techniques. Cell. Mol. Life Sci. 2003, 59, 1681-1689.
46. (d) Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. PAMPA - a useful tool in drug discovery. Eur. J. Pharm. Sci., in press.
47. (e) Kansy, M.; Avdeef, A.; Fischer, H. Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists. Drug Discovery Today: Technol. 2005, 1, 349-355.
48. (f) Ruell, J. A.; Avdeef, A. Absorption Using the PAMPA Approach. In Optimization in Drug Discovery: In Vitro Methods; Yan, Z.; Caldwell, G.W., Eds.; The Humana Press: Totowa, NJ, 2004; pp 37-64.
49. Wang, Q.; Zhang, Y.; Hall, J. P.; Lin, L.-L.; Raut, U.; Mollova, N.; Green, N.; Cuozzo, J.; Chesley, S.; Xu, X.; Levin, J. I.; Patel, V. S. A rat pharmacokinetic/pharmacodynamic model for assessment of lipopolysaccharide- induced tumor necrosis factor-alpha production. J. Pharmacol. Toxicol. Methods 2007, 56, 67-71.